AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03753373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
Study NCT03753373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
Study NCT03753373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
Study NCT00614458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir; valproic acid
Description: raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
Study NCT02899052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 and beyond within 30 minutes to 4 hours after dexamethasone dosing.~Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16; Cycles 19 and beyond, for participants that have not previously transitioned to monotherapy: 27 mg/m2 on Days 1, 2, 15, and 16.~Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - onward: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.~Cycles 2 - onward: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16.
Study NCT02899052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablet administered orally once daily during Cycles 1 - onward. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
Study NCT02899052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablet administered orally during Cycles 1 - onward. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
Study NCT02118207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic running exercise
Description: 60 min of aerobic intervals completed prior to SCUBA diving
Study NCT01953627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedure with the system Kymerax
Study NCT01953627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The system Kymerax
Study NCT00568152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low PA apple puree
Description: Golden Delicious apple puree 230grams consumed daily for 14 days
Study NCT00568152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High PA apple puree
Description: High PA apple puree (Mitchalin) consumed daily for 14 days
Study NCT00568152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 75mg dispersable aspirin taken daily for 14 days
Study NCT02509520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)
Description: The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver \~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
Study NCT01375569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Study NCT03125824 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Soliton Acoustic Wave Device
Description: Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
Study NCT02496221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albiglutide 50 mg
Description: Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
Study NCT02496221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
Study NCT02496221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCK (Kinevac)
Description: CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
Study NCT02226939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILN 2061 ZW
Study NCT02226939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02023788 — intervention group
Intervention type: BIOLOGICAL
Intervention: PNEUMOSTEM
Description: A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10\^7 cells/kg High Dose Group (6 patients): 2.0 x 10\^7 cells/kg~\* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study.
Study NCT01514656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Training using the Family and Friends CPR Anytime Video Self Instruction
Description: Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
Study NCT01514656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR Training using the Family and Friends CPR Anytime Video Self Instruction
Description: Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
Study NCT03812458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: website and brochure
Description: website and brochure
Study NCT02964845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WISH with CHW and referral to HFM
Description: 6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
Study NCT02964845 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Treatment as Usual
Description: Linkage to Primary care.
Study NCT02015897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical TherapyA
Description: Group A:~* Skin care~* Manual lymphatic drainage~* Bandaging using Coban™2Lite~* Guidance on physical activity
Study NCT02015897 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Physical TherapyB
Description: Group B:~* Skin care~* Bandaging using Coban™2Lite~* Guidance on physical activity
Study NCT02796339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mastiha
Study NCT02796339 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab 1200 mg IV infusion Q21D (Cohorts C and F) or 1680 mg IV infusion Q4W starting on Day 29 (Cohort E).
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive pemetrexed 500 mg/m\^2 IV infusion on Day 1 Q21D.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Participants will receive cisplatin 75 mg/m\^2 IV on Day 1 Q21D.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive gemcitabine 1000 or 1250 mg/m\^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Participants will receive entrectinib 600 mg orally QD.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive 60 mg PO QD on Days 1-21 of the initial run-in and triple-combination periods.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants will receive 960 mg PO BID on Days 1-21 of the initial run-in period, and 720 mg PO BID on Days 22-28 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
Study NCT01514656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation of a Hospital-based CPR Training Model
Description: Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
Study NCT03178552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive 15 mg/kg of IV bevacizumab on Day 1 of each 21-day cycle during the induction and maintenance periods.
Study NCT01514656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up prompting to encourage skill retention
Description: Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
Study NCT03330197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad-RTS-hIL-12
Description: 2.0 x 10\^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
Study NCT03330197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Veledimex - Arm 1 (Pediatric Brain Tumor)
Description: 1 dose level (10mg/day) 15 oral daily doses of veledimex
Study NCT03330197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Veledimex - Arm 2 (DIPG)
Description: 2 dose levels (10mg/day, 20mg/day) 14 oral daily doses of veledimex
Study NCT02659488 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lisdexamfetamine
Description: 20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
Study NCT04343989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab 25 mg
Description: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 25 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 25 mg clazakizumab will be given no later than day 3.
Study NCT04343989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazakizumab 12.5 mg
Description: The first dose will be administered as soon as possible after the patient is enrolled and randomized into the Clazakizumab 12.5 mg arm. The route of administration will be intravenous. Each dose will be administered as an infusion that is run over 30 minutes. Serum CRP will be evaluated at baseline and on days 1 and 2 following clazakizumab administration. If the CRP does not decrease by 50% within 36-48 hours after the first dose, a second dose of 12.5 mg clazakizumab will be given no later than day 3.
Study NCT04618952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium D
Description: calcium D supplementation given to postmenopausal females
Study NCT04618952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01327638 — intervention group
Intervention type: DRUG
Intervention: etoricoxib
Description: Patients with SpA/AS who took etoricoxib
Study NCT01327638 — intervention group
Intervention type: DRUG
Intervention: Other COX-2 inhibitor
Description: Patients with SpA/AS who took other COX-2 inhibitors
Study NCT01327638 — intervention group
Intervention type: DRUG
Intervention: nsNSAIDs
Description: Patients with SpA/AS who took nsNSAIDs
Study NCT01559831 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: IXIARO
Description: Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
Study NCT01358019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Days 1, 2, and 3 in a cycle that consists of 21-days
Study NCT01134588 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper questionnaire
Study NCT01134588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touch screen questionnaire
Study NCT02322242 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Systemic Dexamethasone
Description: Intravenous infusion of dexamethasone (4mg)
Study NCT02322242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perineural dexamethasone
Description: Perinerual administration of dexamethasone (4mg)
Study NCT03996707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Weight Bearing
Description: Immediate protected weight bearing in a CAM walking boot following foot \& ankle surgery
Study NCT03996707 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strict non-weight bearing
Description: Strict non weight bearing for 6 weeks following foot \& ankle surgery
Study NCT04368325 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum creatinine levels
Description: Comparison of treatment length using mechanical ventilaton, length of stay in ICU, survival between two groups
Study NCT00891878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT00891878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally
Study NCT02122510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacine group
Description: Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
Study NCT02122510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
Study NCT01291719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glucose and insulin infusions
Description: combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
Study NCT03845322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin Pill
Description: Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day). According to the Company, each capsule contains: 270 mg of pure curcuminoids (curcumin) and 3 mg of black pepper extract. Recommended serving size is 3 capsules per day in total, the patients will receive 810 mg of pure curcumin and 9 mg of black pepper extract (peperine/BioPerine) per day.
Study NCT03845322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
Study NCT03459833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
Study NCT03459833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hyaluronic Acid
Description: Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
Study NCT01595074 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: Correlative studies
Study NCT01595074 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01127386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25mg od, dose reduction according to toxicity
Study NCT01127386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
Study NCT01127386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)
Description: twice during study
Study NCT01542736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered concurrently with craniospinal radiation.
Study NCT01542736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Administered concurrently with craniospinal radiation.
Study NCT01542736 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 24 Gy
Description: Craniospinal radiation.
Study NCT02038400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KINETUBE medical Device
Study NCT02038400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insertion of tympanic ventilation tubes (tympanostomy)
Study NCT01644578 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Real-time imaging for MRI-guided procedures
Description: Real-time imaging for improvement of workflow in MRI-guided procedures
Study NCT00720733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skills-Building Intervention
Description: A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.